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 Abstract 
Wharton’s jelly is a non-controversial source of mesenchymal stromal cells.  Isolation of 
the cells is non-invasive and painless.  The cells have been shown to have a wide array of 
therapeutic applications.  They have improved symptoms when transplanted in a variety of 
animal disease models,  can be used in tissue engineering applications to grow living tissue ex 
vivo for transplantation, and can be used as drug delivery vehicles in cancer therapy.  The cells 
have also been shown to be non-immunogenic and immune suppressive.  This thesis focuses on 
optimizing isolation protocols, culture protocols, cryopreservation, and characterization of cells 
in different growth conditions. 
Results from the experiments indicate that isolation of cells by enzyme digestion yields 
cells consistently, a freezing mixture containing 90% FBS and 10% DMSO confers maximum 
viability, and the expression of mesenchymal stromal cell consensus markers does not change 
with passage and cryopreservation.  The results of the experiments also show that cells grow at a 
higher rate in 5% oxygen culture conditions compared to 21% oxygen culture conditions, serum 
does not have an effect on growth of the cells, serum and oxygen do not have effects on the 
expression of mesenchymal stromal cell consensus markers and the cells are stable without 
nuclear abnormalities when grown in 5% oxygen and serum free conditions for six passages after 
first establishing in serum conditions.
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CHAPTER 1 - Wharton’s Jelly Cells – Introduction and Background 
Stem Cells 
Any cell that exhibits the properties of self renewal, differentiation potential and 
engraftment is defined as a stem cell1.  Based on the stage of development from which they are 
isolated, stem cells are categorized to embryonic stem cells, embryonic germ cells, fetal stem 
cells, cord blood stem cells and adult stem cells.  Based on the potency, stem cells are totipotent, 
pluripotent, or multipotent/oligopotent.  Totipotent cells give rise to all the tissues of an animal 
including extra embryonic membranes, the example for which is the zygote.  Pluripotent stem 
cells give rise to tissues of all three germ layers. Examples for pluripotent stem cells are 
embryonic stem cells and embryonic germ cells2.  Multipotent stem cells give rise to tissues of 
more than one germ layer, the example for which is bone marrow, liver and heart derived 
mesenchymal stem cells3.   
Wharton’s Jelly Cells 
The International Society for Cellular Therapy (ISCT) has laid down defining criteria for 
mesenchymal stromal cells (MSCs). MSCs are plastic adherent, express surface epitopes clusters 
of differentiation 73 (CD73), CD90 and CD10, lack expression of CD34, CD45, CD14, CD11b, 
CD79α , and human leukocyte antigen (HLA)- DR, and have the ability to differentiate into 
osteoblasts, adipocytes and chondrocytes in vitro4.  Wharton’s jelly cells satisfy all three criteria 
and can be called mesenchymal stromal cells 5-11.  Wharton’s jelly cells meet the in vitro 
definition of MSCs.  It is believed that Wharton’s jelly cell isolates are a mixed population of 
cells and may contain a subpopulation of more primitive “stemmy” cells.  To be called stem 
cells, Wharton’s jelly cells must demonstrate long-term engraftment and contribute to 
differentiated tissues in the adult (characteristics which have not been shown yet).  So here 
Wharton’s jelly cells are considered as mesenchymal stromal cells. 
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 Characteristics of the Umbilical Cord 
Six regions have been identified in umbilical cord.  The layers are surface epithelium 
which is amniotic epithelium for most species, subamniotic stroma, clefts, intervascular stroma, 
perivascular stroma and vessels. The intervascular stroma is called Wharton’s jelly 12.  There are 
two arteries and a vein in the normal human umbilical cord.  Wharton’s jelly is a reservoir of 
peptide growth factors including Insulin-like Growth Factor (IGF-1), Fibroblast Growth Factor 
(FGF), and Epidermal Growth Factor (EGF). 13 
Properties of Human Wharton’s Jelly Cells 
Wharton’s jelly contains fibroblastoid stellate-shaped cells that are abundant in 
cytoplasm.  The basement membrane covers only part of the cell membrane as opposed to total 
absence of basement membrane in fibroblast cells 14.  Early  in  development, the blood forming 
cells and germ cells migrate through the region that becomes the umbilical cord and it may be 
that the cells remaining in the  umbilical cord provide support to those cells and keep them from 
differentiating 12;15. 
Growth/culture Characteristics 
Wharton’s jelly cells have been reported to have population doubling times ranging from 
85 hours at passage zero, 11 hours at passage seven, to a population doubling time of 26 hours at 
passage 20 after which they senesce5;7.  Wharton’s jelly can successfully be frozen with high 
percentages of post-thaw viability with a freezing mixture containing 90% FBS and 10% 
DMSO.16 
Immunophenotype 
Flowcytometry analysis revealed that Wharton’s jelly cells express the surface markers 
cluster of differentiation (CD) CD13, CD44, CD90, CD54, CD49b, CD105, human leukocyte 
antigen (HLA class I) HLA-ABC (a few cells express HLA-ABC) and lack the expression of 
CD34, CD45, and HLA-DR (HLA-class II) 6;17.   
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 In vitro differentiation potential  
Wharton’s jelly cells can be differentiated to osteoblasts, adipocytes and chondroblasts 
5;8;10;18.  Wharton’s jelly cells have the potential to differentiate to neurons and glia 19-21, 
cardiomytocytes 22, muscle 23 and endothelial cells 24. 
Immune properties 
In vitro, Wharton’s jelly cells are not immunogenic and suppress the multiplication of 
activated T lymphocytes25.  In vivo, Wharton’s jelly become immunogenic when transplanted 
into inflamed site or following in vitro exposure to IFN-γ26.  In one study, it has been shown that 
fibroblasts derived from skin are more immunogenic compared to fibroblasts derived from 
Wharton’s jelly27. 
Tissue engineering applications 
Pulmonary conduits28, cardiovascular constructs 29;30, and living heart valves31-33 can be 
made in vitro by seeding Wharton’s jelly cells on bio-absorbable polymers.  Wharton’s jelly cells 
have the capacity to differentiate to bone in vivo when injected subcutaneously into nude mice 34.  
Wharton’s jelly cells can also be used in engineering temporo-mandibular joint condylar 
cartilage in vitro 35.  It has been shown that Wharton’s jelly cells perform better than temporal 
mandibular joint condylar cartilage cells for tissue engineering applications36 
Transplantation into disease models 
When undifferentiated pig Wharton’s jelly cells are injected into the  rat brain, a 
significant increase in the number of tyrosine hydroxylase-positive cells are found by 8wks with 
no frank signs of immune rejection 37.  Wharton’s jelly cells improve the symptoms or prevent 
further degradation of behavior when transplanted in a rat model of Parkinson’s disease 38;39.  Rat 
Wharton’s jelly cells may temper  inflammatory responses when used in a global ischemia model 
and may confer neuronal protection40;41.  Wharton’s jelly cells protect photoreceptors and restore 
vision in rat model of retinal disease42.  Wharton’s jelly cells migrate to and survive in infarcted 
myocardium after injection into the heart and improve cardiac function 43.  When Wharton’s jelly 
cells are injected intracerebrally into rats  with ischemic neural tissue, improvement in 
neurological function is noticed44.  Wharton’s jelly cells improve blood flow to hind limb 
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ischemic regions when injected intramuscularly45;46.  Wharton’s jelly cells can be differentiated 
to pre-insulin cells in vitro and when those cells were transplanted into a rat model of diabetes, 
blood glucose levels went down, human insulin was found in peripheral blood correlated with 
blood glucose levels, and growth rate was normalized 47.  Wharton’s jelly cells can be 
differentiated to hepatocytes and successful engraftment of the differentiated cells is observed48.  
A recent study has shown that Wharton’s jelly cells contribute to recovery in spinal cord injured 
rats49. 
Feeder support 
Wharton’s jelly cells provide stromal support for hematopoietic stem cells, natural killer 
cells and also aid in cord blood engraftment 50-52.  Wharton’s jelly cells can be used as a feeder 
layer to maintain primate embryonic stem cells in culture53. 
Homing to cancer site in vivo 
Wharton’s jelly cells home to cancer tissue area and engineered Wharton’s jelly cells 
reduce tumor burden via targeted delivery of cancer drugs54;55. 
Wharton’s jelly cells from non human species 
There are published reports that indicate the successful isolation, culture and 
characterization of Wharton’s jelly cells from pigs and horses56;57,  in addition to rats, mice, 
cattle, dogs and cats (Troyer, Davis, Weiss, and Grieger labs, unpublished). 
  The work done so far indicates that Wharton’s jelly cells offer a promising alternative to 
bone marrow derived stromal cells that are in clinical trials today.  Wharton’s jelly cells have 
advantages including their noncontroversial source, inexhaustible supply, and noninvasive 
collection procedure compared to bone marrow derived stromal cells. 
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CHAPTER 2 - Isolation, culture and cryopreservation of Wharton’s 
Jelly Cells 
Abstract 
The umbilical cord is a non-controversial source of mesenchymal-like stem cells. 
Mesenchymal-like cells are found in several tissue compartments of umbilical cord, placenta and 
decidua. Here, we confine ourselves to discussing mesenchymal-like cells derived from 
Wharton’s jelly; called Wharton’s jelly Cells or Umbilical Cord Matrix Stromal 
Cells(UCMSCs).  Work from several laboratories shows that these cells have therapeutic 
potential, possibly as a substitute cell for bone marrow-derived mesenchymal stem cells for 
cellular therapy.  There have been no head-to-head comparisons between mesenchymal cells 
derived from different sources for therapy; therefore relative utility is not understood.  In this 
chapter, the isolation protocols of the Wharton’s jelly-derived mesenchymal cells are provided as 
are protocols for their in vitro culturing and storage. The cell culture methods provided will 
enable basic scientific research on the UCMSCs.   Our vision is that both umbilical cord blood 
and UCMSCs will be commercially collected and stored in the future for pre-clinical work, 
public and private banking services, etc.  While umbilical cord blood banking Standard 
Operating Procedures (SOPs) exist, the scenario mentioned above requires clinical-grade 
UCMSCs.  The hurdles that have been identified for the generation of clinical-grade umbilical 
cord derived mesenchymal cells are discussed. 
Introduction 
Mesenchymal stem cells (MSCs), as defined by the International Society for Cellular 
Therapy, are plastic-adherent cells with a specific surface phenotype that have the capacity to 
self-renew and have the capacity to differentiate into various lineages including bone, cartilage 
and adipose4.  Such cells can be derived from several different sources such as trabecular bone, 
adipose tissue, synovium skeletal muscle, dermis, pericytes, blood and bone marrow58.  
5 
MSCs derived from bone marrow and adipose tissue have been studied extensively.   
MSCs derived from bone marrow can be differentiated into bone, cartilage, tendon, muscle, 
adipose tissue and hematopoietic cell-supporting stroma 59. Thus, they are candidates to treat 
patients suffering from bone disorders, heart failure, etc.  Since MSCs can be isolated from 
adults in significant number, they have been examined closely for therapeutic utility.  For 
example, MSCs support the ex vivo expansion of hematopoietic stem cells60;61 , act as immune 
modulators62,  release cytokines and growth factors63 and home to sites of pathology 64.   
It is estimated that more than 50 clinical trials are on-going using bone marrow-derived 
MSCs for a variety of indications, for example, acute myocardial infarction, stroke, graft versus 
host disease, etc .  Nevertheless, there are limitations associated with MSCs derived from bone 
marrow for cell-based therapy.  For example, collection of MSCs from bone marrow is an 
invasive and painful procedure.  In normal aging, the marrow cavity fills with yellow fat.  Thus, 
there may be difficulty in obtaining MSCs from older individuals.  Along these lines, differences 
have been found between bone marrow derived MSCs collected from the fetus versus adult-
derived MSCs.  For example, fetal MSCs have a longer life in vitro compared to adult-derived 
MSCs65:  MSCs derived from adults have a useful lifespan in vitro of about five passages58. 
In addition to bone marrow, MSCs may be derived from adipose tissue.  While adipose-
derived MSCs (ASCs) have been studied less than bone marrow-derived MSCs, ASCs may be 
induced to differentiate into osteocytes66, cartilage67  and cardiomyocytes 68;69, and display both 
similar surface phenotype and immune properties to bone marrow-derived MSCs.  While there is 
no shortage of the adipose material within the United States, the procurement of adipose tissue 
involves an invasive and painful surgical procedure.  There is no comparison work done to 
evaluate ASCs from the fetus with adult-derived ASCs. 
Our lab11 (Weiss et al., 2006a) and others70;71  have demonstrated that the cells derived 
from the Wharton’s jelly in umbilical cords (so called Wharton’s jelly cells or UCMSCs) have 
properties of MSCs.  While UCMSCs have surface phenotype, differentiation capability 72  and 
immune properties similar to MSCs derived from bone marrow and adipose25, they are more 
similar to fetal MSCs in terms of their in vitro expansion potential.  In contrast to bone marrow- 
and adipose-derived MSCs, UCMSCs are isolated from the umbilical cord following birth and 
may be collected following either normal vaginal delivery or cesarean section.  As described 
below, UCMSCs are easily expandable in vitro, and may be cryogenically stored, thawed and 
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reanimated.  While the collection process for human materials is elaborated here, UCMSCs have 
been also isolated using modified protocols from dog, cat, rat, mouse, horse, bovine and swine 
umbilical cord.  Human UCMSCs grow as plastic-adherent cells, express a surface phenotype 
similar to other MSCs17  and differentiate to multiple lineages73.  Wharton’s jelly cells have been 
safely transplanted and ameliorated symptoms in an animal model of Parkinson’s disease 17;39; 
neural damage associated with cardiac arrest/resuscitation43, retinal disease 74 and cerebral global 
ischemia41.  Finally, UCMSCs that have been mitotically-inactivated can be used as a feeder 
layer for embryonic stem cells 75. 
Materials and Methods 
Isolation of cells 
Use of umbilical cord tissue from human subjects requires Institutional Review Board 
(IRB) approval and a signed informed consent form.  Umbilical tissue falls into an interesting 
niche.  On one hand, it is a discarded, (potentially) anonymous tissue, and thus, may qualify for 
an IRB exemption.  However, since DNA testing makes UCMSCs individually identifiable, an 
IRB may assign a protocol number and track the work. Once you secure IRB approval, you must 
find an Obstetrics/Gynecology physician and OB/GYN staff at a local hospital to assist; this is 
key to obtaining a steady supply of umbilical material.  The informed consent outlines your 
project, and must be signed by the donor, and witnessed.  The consent form is retained by your 
OB/GYN collaborator to maintain donor confidentiality.  We collect anonymous biographic 
information.  For example, the sex of donor, weeks of gestation, normal or c-section delivery, 
approximate cord length, pre-eclampsia, twins, etc are recorded.  Cords are specifically excluded 
from individuals with questionable health status, for example, stillbirth, pre-eclampsia, infectious 
disease, STD or Hepatitis-positive mother.  After the delivery of the baby, the umbilical cord is 
collected and stored in a sterile specimen cup containing 0.9% Normal Saline at 40˚C until 
processing.  Typically, the cord is processed within 12-24 hrs of birth.  The cord is handled in an 
aseptic fashion and processed in a Type II Bio Safety Cabinet.  The surface of the cord is rinsed 
in phosphate buffered saline to remove as much blood as possible.  The length of the cord is 
estimated.  Cord is manipulated in a sterile 10 cm Petri dish.  The cord is cut into 3-5 cm long 
pieces using sterile blade.  Blood vessels are removed from each piece after incising the cord 
lengthwise. Remaining tissue is rinsed.  The cord tissue is placed into two  sterile 50 ml 15 ml 
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centrifuge tubes with 25 ml of enzyme solution in each one and incubated for one hour at 37˚C.  
(Collagenase Type I, Invitrogen cat# 17100-017 @300units/ml;  Hyaluronidase from ovine 
testes, Fisher cat # ICN15127202 @ 1mg/ml in Phospahate Buffered Saline with 3mM CaCl2)   
After one hour, the cord pieces are crushed using serrated thumb forceps to release as many cells 
as possible into the solution.  The tissue is moved to a new sterile 10 cm2 dish filled with 
Phosphate Buffered Saline, swirled for 5 minutes and moved to a new centrifuge tube containing 
enzyme solution (Trypsin EDTA, Invitrogen cat# 25200-106 @0.1%). The tube is incubated for 
30 minutes at 37˚C. During this incubation, the centrifuge tube containing solution A is 
centrifuged at 1000rpm for 5 minutes. The supernatant is discarded and 3 milliliters of medium 
(Low glucose DMEM, Invitrogen cat #11885 @ 56%; MCDB 201 PH 7.4, sigma cat# M-6770 
@ 37%; Insulin-transferrin-selenium 100X , Invitrogen cat#5150056 @ 1%; Dexamethasone, 
Sigma D-4902 @ 1nM; Ascorbic acid-2 Phosphate, Sigma cat # A-8960 @ 100μM; 
Penicillin/Streptomycin 100X, Invitrogen cat #15140 @ 1%; FBS (Fetal Bovine Serum), Atlanta 
Biologicals cat # S1150 @ 2%; Epidermal Growth Factor, R&D Systems cat# 236-EG-200 @ 
10ng/ml; Platelet-derived growth factor, R&D Systems cat#520-BB-050 @ 10ng/ml; Albumax I 
100X, Invitrogen cat # 111200021 @ 0.15mg/ml) is added to the cell pellet. The cells are 
resuspended in medium by trituration with a 1000μl pipette tip while minimizing bubble 
formation and foaming, and the tube is placed in the incubator until the second enzymatic 
digestion is completed.  After the second enzymatic digestion is complete, the cord pieces are 
squeezed in the enzyme solution to remove as many cells from Wharton’s jelly as possible.  The 
tube is centrifuged at 1000 rpm for 5 min.  The supernatant is discarded and 3 ml of medium is 
added  to the cell pellet.  The cells are resuspended in medium by trituration. The cells from the 
two enzymatic digestion steps are combined.  The live cells are counted using a hemocytometer 
and plated in a 6-well tissue culture plate at a concentration of 30,000 cells per cm2.  The plate is 
incubated at 370C, 5% CO2 for 24-72 h.  After 24-72h, the floating cells are transferred to a new 
plate to allow additional cells to adhere.  The cells in the original plate are fed with fresh 
medium.  The cells are fed by the removal/replacement of half the medium every 2-3 days till the 
cells reach approximately 80% confluence. 
8 
Passaging the Cells 
The cells are passaged when they are 80 – 90% confluent.  The medium is aspirated and 
the cells are rinsed with sterile phosphate buffered Saline (Invitrogen cat # 14190250).  A 
minimum amount of warmed, CO2 – equilibrated 0.05% trypsin – EDTA (Invitrogen cat # 
25200-106) is added to the plate and/or flask to cover the culture surface – 0.5 ml to each well of 
a 6-well plate, 1 ml to a T-25 flask, and 2 ml to a T -75 flask.  The plate and/or flask is allowed 
to sit at room temperature for 1-2 min.  Then the detachment of the cells is observed under a 
microscope and detachment facilitated by repeatedly tapping the plate and/or flask gently on a 
hard surface.  The cells are not allowed to be in contact with trypin-EDTA for more than 5 min.  
The trypsinization reaction is neutralized by adding 2-3 times volumes of medium.  The solution 
containing the cells is transferred to a 15 ml sterile centrifuge tube and centrifuged at 1000 rpm 
for 5 min at room temperature.  The supernatant is discarded and the cells are resuspended gently 
in fresh medium.  The cells are counted and transferred to a new plate or flask at a concentration 
of 10000 cells per cm2 in fresh medium.  The plates and/or flasks are incubated at 37˚C, 
saturating humidity and 5 % CO2.  The plates and/or flasks are checked for confluence every day 
and the cells are fed every other day by removing half the medium and replacing it with fresh 
medium.  1.5 ml, 4 ml and 10 ml of medium is added to one well of a 6-well plate, one T-25 
flask and one T-75 flask, respectively.   
Feeding the cells 
The cells are fed every other day or every 3 days.  Half the medium in the plate or flask is 
aspirated and is replaced with fresh medium. 
Cryopreservaton 
The cells collected for freezing are in the growth phase.  The cells are lifted as described 
for passaging, except that 4˚C freezing medium is added to the cells rather than resuspending 
them in medium.  The cells in the freezing medium are transferred into a cryovial at 4˚C.  The 
cryovial is transferred to a controlled rate cooler, like Mr. Frosty, maintained at 4˚C and placed 
in the coldest part of the -80˚C freezer.  The cryovial is transferred to a liquid nitrogen tank in a 
day or two.  For the experiment, three freezing media were used -  90% FBS & 10% DMSO;  
90% FBS & 10% Glycerol; 50% growth medium, 40% FBS and 10% DMSO ( DMSO, Sigma 
cat #; Glycerol, Fisher cat #;  FBS, Atlanta Biologicals cat#S11150).  Growth medium without 
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any cryoprotectant is used as a control.  The experiment is done with cells from nine umbilical 
cords. The cells are frozen at passage 4 and passage 8.  The cells are stored in liquid nitrogen for 
a month and thawed.  Post thaw  viability is estimated using trypan blue assay and the cells 
frozen in 90% FBS & 10% DMSO  are analyzed for mesenchymal stromal cell markers before 
and after freezing by flowcytometry.  One million cells are frozen per cryovial. For trypan blue 
exclusion assay (Trypan Blue, Invitrogen cat #  @ 0.2%), 40µl of cell suspension is mixed with 
40µl trypan blue and 10µl of that suspension is taken on each side of a hemocytometer.  The 
dead cells take up the dye and the live cells do not.  The live and dead cells are counted in the 
four white blood cells squares on each side and an average is calculated.  The number is 
multiplied by 10,000 and further by 2 to get the number of cells in one ml of medium.   
Flowcytometry 
The cells are lifted as described in passaging and are resuspended in phosphate buffered 
saline at 1-2 million/ml.  100 µl of this cell suspension is taken in each of 12 X 75 mm Falcon 
polystyrene FACS tubes.  The appropriate amount of conjugated antibody or isotype control is 
added to each FACS tube ( PE isotype control IgG1, BD Biosciences cat # 555749 @ 10µl/100µl 
cell suspension; FITC isotype control IgG2b, BD Biosciences cat # 556655 @  10µl/100µl cell 
suspension; PE CD13 IgG1, BD Biosciences cat # 555394 @ 10µl/100µl cell suspension; PE 
CD44 IgG2b BD Biosciences cat # 556655 @ 10µl/100µl cell suspension; PE CD49e IgG1, BD 
Biosciences cat # 555617 @  10µl/100µl cell suspension; PE CD90 IgG1 BD Biosciences cat # 
555596 @ 5µl/100µl cell suspension; PE CD105 IgG1, Fitzgerald cat # RDI CD105NPE  
@3µl/100µl cell suspension).  Tubes are incubated at room temperature in the dark for 15-20 
min.  After the incubation, the cells are washed with 2 ml of phosphate buffered saline (Ca2+ 
free) and run through a flowcytometer.  Typically for each tube, 10000 events are collected and 
the data are analyzed using Cell Quest software. 
Parts of this chapter are adapter from Chapter 6 authored by Kiran babu Seshareddy et 
al., published in Stem Cell Culture, Methods in Cell Biology Series, Volume 86 page no. 101-
119. 
Statistical analysis 
ANOVA was used to test overall significance and interactions of main effects for 
normally distributed variables. Normality of the data was tested using Kolmogorov-Smirnov test. 
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Data was re-evaluated for normality following transformation (sine function used here).  Post 
hoc testing using Bonnferroni/Dunn test was used to evaluate planned comparisons between 
group means.  Data is presented as means (average) plus or minus one standard error of the mean 
throughout.  Significance is defined as p< 0.05.  StatView 5.0.2 was used for statistical testing. 
11 
 Results 
1. 90% FBS and 10% DMSO resulted in maximum viability of the three 
freezing media tested.  ANOVA was used to evaluate the hypothesis that there 
were differences between the different freeze/thaw conditions (different freezing 
medium) or differences in viability over time spent in culture (passage).  The 
main effect Freezing medium was significant: F(4,40) = 111.9, P-value < 0.001.  
The main effect Passage was not significant, indicating that no significant 
difference was observed between the viability at Passage 4 and Passage 8. 
ANOVA revealed a significant interaction effect (Freezing medium X Passage) 
F(4,40) = 3.7, P-value<0.01.  The interaction term was not evaluated further.  To 
evaluate the main effect: Freezing medium, post hoc analysis using 
Bonferroni/Dunn test was used to evaluate pre-planned comparisons (alpha set at 
5% for significance).   There were significant differences between all conditions 
tested except there was no significant difference in viability between FBS+DMSO 
and FBS+ DMSO + Medium.  As can be seen in figure 2.1, 90% FBS + 10% 
DMSO produced the greatest numerical percentage of viable cells.   Freezing in 
DM(Defined Medium) alone produced significantly lower percentage of viable 
cells than the other groups (this is the positive control).  Freezing the cells 
damaged them since the  cells that were not frozen (BF(Before Freezing) group, 
the negative control) had significantly greater percentage of viable cells than the 
freeze/thaw groups. 
2. There is no change in expression of surface markers before and after freezing 
over passage.  The percentage data was tested for normality using the 
Kolmogorov-Smirnov test.  It was found to be not normal.  Thus, a sine function 
transformation was applied to the data.  The data was then tested again and found 
to be normally distributed.  ANOVA was used to evaluate the main effect 
Freeze/thaw (between subjects) and surface markers (five levels: CD13, CD44, 
CD49e, CD90 and CD105).  The hypotheses were that freeze/thaw did not have 
significant effect on expression of surface markers CD13, CD 44, CD 49e, CD 90 
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and CD 105 and that there would be a difference in the expression of surface 
markers.  The main effect Freeze/thaw was not significant: F (1,80) = 0.22, P-
value>0.05.  The main effect surface markers was significant:  F (4, 80) = 5.72, P-
value < 0.05.;  
Discussion 
Here, a reliable, standardized laboratory method for isolation, expansion, freezing and 
thawing and characterization of Wharton’s jelly cells (WJCs) was provided. This method used 
the enzymatic digestion of the extracellular matrix using trypsin, collagenase and hyluronidase to 
liberate WJCs prior to plating.  Four different freezing conditions were evaluated to determine 
the optimal freezing medium.  The WJCs were evaluated for their stability of surface marker 
expression over passage and after freeze/thaw and re-expansion.   
In addition to the enzymatic method, cells from the Wharton’s jelly can be isolated using 
another method called the “Explant Method.”  For this method, the tissue is chopped into small 
pieces, about 1 cm2, and plated with medium.  The explants attach to the substrate and the cells 
outgrow from the tissue. These cells are harvested and passaged. The shortcoming with the 
explant method is the inability to determine the number of cells that have been isolated from the 
cord at the initial passage because the cells continue to outgrow from the explants even after the 
cells have been harvested.  If one wishes to bank Wharton’s jelly cells from initial isolation 
without expansion, the explant method has been previously reported to maintain the viability of 
WJCs and can be collected with minimal manipulation (Podja’s abstract).  With the enzymatic 
digestion method, the number of cells isolated from the umbilical cord is dependent upon the 
effectiveness of enzymatic digestion.  The method provided here produces about 15,000 cells / 
cm2.  More complete digestion of the Wharton’s jelly produces significantly greater cell yields at 
the primary isolation step (D. Davis, personal communication).   
Based on the experimental results, 90% FBS and 10% DMSO produced maximum post 
thaw viability.    
The cells were analyzed for surface expression of CD13, CD44, CD49e, CD90 and 
CD105 by flow cytometry since these are accepted as mesenchymal stromal cell markers76.  The 
expression of surface markers was not affected by freezing.  Since expression was not 
statistically changed, this suggests that freezing the cells did not affect the population of cells.  
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This conclusion holds for the markers evaluated here.  It is possible that other surface markers 
which were not evaluated here, such as CD146, CD140b, markers thought to be on the most 
stemmy MSC population, may be affected by the freeze thaw cycle.  Further work is needed to 
confirm our results.  These results do suggest that the thawed cell product is not fundamentally 
changed and would support the use of thawed cells as an off-the-shelf cell therapy product. 
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Figure 2.1 90% FBS + 10% DMSO produced the greatest percentage of viable cells.   While 
the percentage of viable cells in the experimental groups was numerically highest in DMSO 
+ FBS, there is no significant difference in viability between FBS+DMSO and 
FBS+DMSO+Medium groups. 
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Figure 2.2 The overall viability is not different between P4 and P8. 
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Figure 2.3 Flowcytometry histogram of surface marker expression between passage 4 and 
passage 8 before freezing. 
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Figure 2.4 Flowcytometry histogram of surface marker expression between passage 4 and 
passage 8 before freezing. 
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 CHAPTER 3 - Characterization of Wharton’s jelly cells in different 
growth conditions 
Introduction 
Wharton’s jelly cells:  Wharton’s jelly is a non controversial and inexhaustible source of 
mesenchymal stromal cells.  The cells meet all the criteria laid down by ISCT for mesenchymal 
stromal cells.  The cells have been shown to have therapeutic effect in various disease models.  
Cells have been characterized using growth medium that contains serum from animal source. 
FBS (Fetal Bovine Serum) and Stem Cells 
FBS (Fetal Bovine Serum) (FBS) is a vital component of medium used to culture  stem 
cells.  Since serum used by different labs is sourced from different suppliers, the experimental 
results of the comparable experiments are not same77.  The growth of the cells varies with lot 
differences of FBS78.   Bone marrow mesenchymal stem cells have been shown to become  
immunogenic after transplantation, when they are grown in medium containing FBS (Fetal 
Bovine Serum)79;80.  In one study, when lymphocytes grown in medium containing FBS (Fetal 
Bovine Serum) were infused in patients suffering from Human Immunodeficiency Virus (HIV) 
infection, the recipients developed arthus-like reactions due to FBS (Fetal Bovine Serum) 
components81.  In another gene therapy clinical trial for adenosine deaminase deficiency, the 
patients developed IgG immunity to FBS (Fetal Bovine Serum) proteins after they were infused 
with T cells grown in medium that had FBS (Fetal Bovine Serum) as one of its components82.  It 
is shown that photosensitizer proteins found in FBS (Fetal Bovine Serum) bind to cells in human 
serum, possibly one of the mechanisms underlying the immunogenic nature of human cells 
grown in medium supplemented with FBS (Fetal Bovine Serum)82;83.  When adipocyte 
progenitor cells are culture in the medium with FBS (Fetal Bovine Serum), enhanced activity of 
glycerophosphate dehydrogenase, an adipocyte differentiation marker, is observed84.  Beta 2-
microglobulin, present in high concentrations in FBS (Fetal Bovine Serum), promotes peptide 
binding to MHC I (Multi Histocompatability Complex) molecules on the cultured cells making 
19 
them unstable85.  Proliferative capacity of adult neural progenitor cells is reduced when they are 
grown in medium containing FBS (Fetal Bovine Serum) compared to the medium without FBS 
(Fetal Bovine Serum)86.  Bovine fetuin, a glycoprotein present in FBS (Fetal Bovine Serum), is 
shown to have effect on the differentiation and growth of cells in culture87;88.  The differentiation 
potential of bone marrow stromal cells has been shown to be very high in serum free system89.  
For the reasons stated above and several others, to be able to use cells for therapeutic purposes, 
they have to be grown in animal serum free medium90.  When grown in serum free medium, 
multilineage differentiation was shown in human placenta and bone marrow derived 
mesenchymal stem cells91.  
Hypoxia and Stem Cells 
Normal physiological oxygen concentration for embryonic and adult cells is in the range 
of 2-9%92.  Hypoxia conditions exist in developing embryo and adult, which control 
differentiation of cells93.  Stem cells reside in specified areas called niches in the body where 
hypoxic conditions exist94.  Human trophoblast stem cells proliferate without undergoing 
differentiation when grown in 3% oxygen conditions95.  Bone marrow mesenchymal stem cells 
from rat show increased colony forming ability and proliferation when grown in 5% oxygen 
conditions compared to 21% oxygen conditions96.  When bone marrow hematopoietic stem cells 
are grown in 1.5% oxygen, their engraftment capacity increases in immnocompromised recipient 
mice.  When grown in low oxygen conditions, bovine blastocysts showed more inner cell mass 
when compared to blastocysts grown in normoxic conditions97.  It has been shown that when 
human embryonic stem cells are grown in 3-5% oxygen culture conditions as opposed to 21% 
oxygen, they retain the expression of Oct-4 and SSEA98.  Increased proliferation of rat CNS 
derived multipotent stem cells and fetal derived neural crest  cells is reported when grown in low 
oxygen conditions99;100.  Low oxygen tension promotes the maintenance and enhanced 
proliferation of cord blood progenitors101;102.  It is reported that stem cells reside in low oxygen 
niche of marrow and kidney103;104.  Studies show that low oxygen plays a vital role in 
mobilization of stem cells from bone marrow in disease105.  In low oxygen conditions, cells 
senesce later and DNA damage is reduced106.  Studies have shown that CD34+ progenitor cells 
and fetal rat derived CNS stem cells undergo reduced apoptosis when they are grown in reduced 
oxygen conditions100;107.  It is reported that when bone marrow derived multipotent stromal cells 
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are cultured in low oxygen conditions, their expression of CX3CR1 is enhanced and they also 
show an enhancement in engraftment in vivo108. 
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 There is also evidence that hypoxia accelerates the proliferation and differentiation of 
marrow derived mesenchymal stromal cells109.   
Materials and Methods 
Isolation of Wharton’s jelly cells 
Human Umbilical Cord is obtained with the informed consent of mother.  The collected 
cord is placed in sterile saline and stored at 4˚C until it is processed.  The umbilical cord is 
processed within 24 hours of its collection, under sterile conditions in a biosafety cabinet (BSC). 
Dulbecco’s Phosphate Buffered Saline (Invitrogen, cat # 14190-250) to remove blood that oozes 
out of the vessels.  Each tissue piece is slit open length-wise and the blood vessels are removed.  
Tissue is then digested in the collagenase and hyaluronidase enzyme solution at 37˚C for 45 
minutes in an incubator.  After 45 minutes, the enzyme solution with tissue is taken out and put 
in the stomacher bags (BA 6141/STR filter bags, Brinkmann cat # 0300202) with inner tissue 
filter at the rate of 25 ml of enzyme solution per bag.  The air in the bag is removed to prevent 
the bag from rupturing and the bag is sealed at least twice at the top using a heat sealer.  The bag 
is placed in the stomacher (Stomacher 400 Circulator by Seward Ltd., U.K. (Brinkmann cat # 
030010159) and the stomacher is run at 150 rpm for 10 minutes at 37˚C.  After 10 min, the bag is 
removed from the stomacher, sprayed with 70% alcohol on the outside and the enzyme solution 
is collected inside a biosafety cabinet by making a small 1 cm opening with sterile scalpel blade 
in the lower end of the bag.  The solution is collected into a sterile specimen cup.  The enzyme 
solution is placed in a centrifuge tube and centrifuged at 1000 rpm for 5 minutes at 20˚C.  The 
supernatant is discarded and the pellet is suspended in 1 ml of growth medium (Low glucose 
DMEM, Invitrogen cat #11885 @ 56%; MCDB 201 PH 7.4, sigma cat# M-6770 @ 37%; Insulin-
transferrin-selenium 100X , Invitrogen cat#5150056 @ 1%; Dexamethasone, Sigma D-4902 @ 
1nM; Ascorbic acid-2 Phosphate, Sigma cat # A-8960 @ 100μM; Penicillin/Streptomycin 100X, 
Invitrogen cat #15140 @ 1%; FBS (Fetal Bovine Serum), Atlanta Biologicals cat # S1150 @ 
2%; Epidermal Growth Factor, R&D Systems cat# 236-EG-200 @ 10ng/ml; Platelet-derived 
growth factor, R&D Systems cat#520-BB-050 @ 10ng/ml; Albumax I 100X, Invitrogen cat # 
111200021 @ 0.15mg/ml).  A cell count is done using a hemocytometer.  The cells are then 
plated in a 6-well tissue culture plate at a density of 15000 – 20000 cells/ cm2.   
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When the cells reach 90% confluence, they are passaged.  The cells are grown in four 
growth conditions -  21% oxygen and growth medium with serum, 21% oxygen and serum free 
medium, 5% oxygen and growth medium with serum and 5% oxygen and serum free medium. 
The recipe for serum free medium is knock out medium, Invitrogen 10829 @ 87%, L-Glutamine, 
Sigma 49419 @ 1mM, B-mercaptoethanol, Sigma M7522 @ 0.1mM, Non Essential amino acids, 
Invitrogen 11140 @0.1%,  b FGF, Invitrogen 13256-029 @ 5ng/ml,  knock-out serum 
replacement, Invitrogen 10828-028 @ 80%.    The cells are grown till passage 6.  At each 
passage 250000 cells are plated in a T 25 flask and cultured for four days in each of the four 
culture conditions. The growth medium with serum recipe is Low glucose DMEM, Invitrogen 
cat #11885 @ 56%; MCDB 201 PH 7.4, sigma cat# M-6770 @ 37%; Insulin-transferrin-
selenium 100X , Invitrogen cat#5150056 @ 1%; Dexamethasone, Sigma D-4902 @ 1nM; 
Ascorbic acid-2 Phosphate, Sigma cat # A-8960 @ 100μM; Penicillin/Streptomycin 100X, 
Invitrogen cat #15140 @ 1%; FBS (Fetal Bovine Serum), Atlanta Biologicals cat # S1150 @ 
2%; Epidermal Growth Factor, R&D Systems cat# 236-EG-200 @ 10ng/ml; Platelet-derived 
growth factor, R&D Systems cat#520-BB-050 @ 10ng/ml; Albumax I 100X, Invitrogen cat # 
111200021 @ 0.15mg/ml. 
Passaging the cells 
The cells are passaged when they are 80 – 90% confluent.  The medium is aspirated off 
and the cells are rinsed with sterile phosphate buffered Saline (Invitrogen cat # 14190250).  A 
minimum amount of warmed, CO2 – equilibrated 0.05% trypsin – EDTA ( Invitrogen cat # 
25200-106) is added to the plate and/or flask to cover the culture surface – 0.5 ml to each well of 
a 6-well plate, 1 ml to a T-25 flask, and 2 ml to a T -75 flask.  The plate and/or flask is allowed 
to sit at room temperature for 1-2 min.  Then the detachment of the cells is observed under a 
microscope and detachment facilitated by repeatedly tapping the plate and/or flask gently on a 
hard surface.  The cells are not allowed to be in contact with trypin-EDTA for more than 5 min.  
The trypsinization reaction is neutralized by adding 2-3 times volumes of medium.  The solution 
containing the cells is transferred to a 15 ml sterile centrifuge tube and centrifuged at 1000 rpm 
for 5 min at room temperature.  The supernatant is discarded and the cells are resuspended gently 
in fresh medium.  The cells are counted and transferred to a new plate or flask at a concentration 
of 10000 cells per cm2 in fresh medium.  The plates and/or flasks are incubated at 37˚C, 
saturating humidity and 5 % CO2.  The plates and/or flasks are checked for confluence every day 
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and the cells are fed every other day by removing half the medium and replacing it with fresh 
medium. For serum free conditions the cells are grown in 0.1% Gelatin coated flasks. 
Counting the cells 
The cells are counted using a hemocytometer. 
Population doubling formula 
Population doubling is calculated using the formula: 
Inverse of     
Flowcytometry 
Flowcytometry is done on the cells grown in four growth conditions for surface markers 
CD13, CD44, CD49e, CD90 and CD105.  The cells are lifted as described in passaging and are 
resuspended in phosphate buffered saline at 1-2 million/ml.  100 µl of this cell suspension is 
taken in each of 12 X 75 mm Falcon polystyrene FACS tubes.  The appropriate amount of 
conjugated antibody or isotype control is added to each FACS tube ( PE isotype control IgG1, BD 
Biosciences cat # 555749 @ 10µl/100µl cell suspension; FITC isotype control IgG2b, BD 
Biosciences cat # 556655 @  10µl/100µl cell suspension; PE CD13 IgG1, BD Biosciences cat # 
555394 @ 10µl/100µl cell suspension; PE CD44 IgG2b BD Biosciences cat # 556655 @ 
10µl/100µl cell suspension; PE CD49e IgG1, BD Biosciences cat # 555617 @  10µl/100µl cell 
suspension; PE CD90 IgG1 BD Biosciences cat # 555596 @ 5µl/100µl cell suspension; PE 
CD105 IgG1, Fitzgerald cat # RDI CD105NPE  @3µl/100µl cell suspension).  Tubes are 
incubated at room temperature in the dark for 15-20 min.  After the incubation, the cells are 
washed with 2 ml of phosphate buffered saline ( Ca2+ free) and run through a flowcytometer.  
Typically for each tube, 10000 events are collected and the data are analyzed using Cell Quest 
software. 
Cell Cycle Analysis 
The cells at passage 4 grown in four different conditions are used for cell cycle analysis.  
One million cells are suspended in each of the 12 x 75 mm tubes.  The cells are fixed  with 70% 
ethanol for 2 hours at 4˚C in 12 x 75mm tubes.  The cells are then washed with PBS.  After 
washing, the cells are incubated with 1 ml of PI/Triton X-100 solution at 37˚C for 15 min.  
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Flowcytometry is performed on the cells and PI emission at red wavelengths is detected.  The 
data is analyzed using DNA content frequency histogram deconvolution software. 
Statistical analysis 
ANOVA was used to test overall significance and interactions of main effects for 
normally distributed variables. Normality of the data was tested using Kolmogorov-Smirnov test 
Data was re-evaluated for normality following transformation (sine function used here).  Post 
hoc testing using Bonnferroni/Dunn test was used to evaluate planned comparisons between 
group means.  Data is presented as means (average) plus or minus one standard error of the mean 
throughout.  Significance is defined as p< 0.05.  StatView 5.0.2 was used for statistical testing. 
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Results 
1. Growth Kinetics : ANOVA shows that the main effect Oxygen concentration has 
a significant effect on cell number; F (1,12)  = 178.8, P-value < 0.01, and the main 
effect Medium was not significant F (1, 12) 0.9, p> 0.05.  ANOVA shows that the 
main effect Passage (within subjects variable) was significant; F (4,48)  = 3.9, P-
value < 0.01.  Post hoc analysis and inspection revealed that the number of the 
cells was significantly higher when grown in 5% oxygen than in 21% oxygen.  
Importantly, the cell number was significantly increased from P2, the first passage 
that the cells were exposed to lower oxygen concentration.   Post hoc analysis 
revealed that the number of cells increased significantly with passage.  Population 
doubling times:  ANOVA shows that the main effect Oxygen concentration was 
significant F (1, 12) 198.6, p<0.05; and the Main effect Doubling time was 
significant F (4, 48) = 4.2, p < 0.05.  The main effect Medium was not significant 
F 1, 12 = 1.57, p > 0.05.  Post hoc analysis revealed that 5% oxygen concentration 
produced significantly faster growth (50.7 + 0.5 hrs population doubling time vs 
61.8 + 0.7 hrs).  Post hoc analysis revealed that the doubling times decrease over 
passage from 58.8 + 1.8 at passage 2 to 54.3 + 1.7 at passage 6. 
2. Flowcytometry:  Flow cytometry revealed that there is no effect of growth 
condition on the expression of surface markers CD 13, CD 44, CD 49e, CD 90 
and CD 105.  The data is gathered for conditions for cells from one isolate.  The 
remaining isolates need to be done.  These results will be added to the completed 
paper that will be submitted to Stem Cells for evaluation. 
3. Cell cycle analysis: DNA content analysis revealed that most of the cells were in 
G0 phase in all the growth conditions.  The data is gathered for conditions for 
cells from one isolate.  The remaining isolates need to be done.  These results will 
be added to the completed paper that will be submitted to Stem Cells for 
evaluation. 
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Discussion 
To translate the therapeutic potential of Wharton’s jelly cells to clinics, the cells have to 
be isolated and grown in serum free conditions.  Until now all the characterization of Wharton’s 
jelly cells has been carried out with cells grown in serum containing medium and 21% oxygen 
tension culture conditions.  The demerits of growing the cells in fetal serum containing medium 
and merits of growing the cells in low oxygen have been discussed in the introduction section of 
the chapter.  The experimental findings suggest that Wharton’s jelly cells proliferate at a higher 
rate in 5% oxygen compared to 21% oxygen.  The serum did not affect the growth of the cells.  
To find out if the properties of the cells change in different growth conditions, we have evaluated 
the expression of cell surface markers grown in four growth conditions and also performed cell 
cycle analysis.  Flowcytometry has revealed that serum and oxygen has no effect on the 
expression of cell surface markers.  Cell cycle analysis revealed that in all four conditions, the 
DNA content of most of the cells was in G1 phase.  This shows that cells are not aneuploid or 
polyploid when grown in serum free and low oxygen conditions. 
The experiments were done with cells isolated from Wharton’s jelly in 21% oxygen 
conditions and serum containing medium.  It would be interesting to see if cells could be isolated 
and maintained in serum free low oxygen tension culture conditions.  The results lay a path for 
clinical translation of Wharton’s jelly cells. 
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Figure 3.1 Top:  The number of cells in the two oxygen concentrations (5% oxygen, low 
oxygen, blue and 21% oxygen (normal oxygen on graph, in red).  5% oxygen significantly 
increased the number of cells starting with passage 2 (P2) and remained greater than 
normal oxygen for all passages observed (P2 through P6).  Bottom:  The serum free 
medium did not have a significant effect on cell number observed in either oxygen 
condition, or across passage (see text). 
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Figure 3.2 Flowcytometry analysis - Histogram plots of expression of cell surface markers 
in serum free and serum conditions at passage 4 grown in 21% oxygen conditions. The 
expression of surface markers does not change with serum or serum free conditions. 
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Figure 3.3 Flowcytometry analysis - Histogram plots of expression of cell surface markers 
in serum free and serum conditions at passage 4 grown in 5% oxygen conditions. The 
expression of surface markers does not change with serum or serum free conditions.
30 
 
Figure 3.4 Flowcytometry analysis -  Cell Cycle Analysis. DNA content is evaluated with 
Propidium Iodide uptake of the cells grown in four growth conditions.  Analysis shows that 
most of the cells are in G1 phase and it is same in all four conditions 
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 CHAPTER 4 - Discussion 
Considering the therapeutic capability of Wharton’s jelly cells, they could potentially be 
used as an alternative to bone marrow derived mesenchymal stem cells in a clinical setting.  The 
cell therapy would be more feasible if the cells could be made available as an off the shelf 
product in frozen state.  Optimization of freezing protocol is vital for this.  To be able to do that, 
optimizing the conditions for freezing is necessary.  There are reports indicating that Wharton’s 
jelly cells could successfully be frozen and revitalized.  Karahuseyingolu et al. have reported that 
only 50% of Wharton’s jelly survive freezing and the growth rate after revitalization positively 
correlates to serum concentration in the medium used to culture after thawing5.  In this study, 
only one freezing medium was used.  Successful attempts have been made to freeze minced 
umbilical cord tissue and start the cells from thawed tissue52, too, but the viability of the tissue at 
thaw was not available.   
We are the first to study the effect of composition of freezing medium on viability of 
Wharton’s jelly cells and its effect of expression of cell surface markers 110.    Since DMSO and 
Glycerol are the commonly used cryoprotectants in freezing mixtures for mammalian cells, we 
compared freezing mixtures containing DMSO and glycerol.  Since previous reports had 
indicated the importance of FBS to freeze/thaw viability111 , we have formulated our freezing 
media based on FBS with other cryoprotectants like Glycerol and DMSO.     Our experiments 
indicate that 90% FBS with 10% DMSO results in maximum numerical viability, although 
statistically, 90% FBS + 10% DMSO was not statistically different from 50% FBS + 10% 
DMSO + 40% Medium.  Along with the viability, it is also important for the freezing medium 
not to select or alter the population of cells through the cryopreservation and subsequent 
freeze/thaw process.  Our experiments also show there is no effect of freezing medium on 
expression of mesenchymal stromal cells’ consensus markers on Wharton’s jelly cells.   This 
would strongly suggest that the population has not been drastically altered.  Further work is 
needed to rule out the possibility that the stemmy population, e.g., the CD146+ / CD140b+ 
population112;113  which may have greater sensitivity to damage compared to stromal cells, is also 
intact following cryopreservation and freeze/thaw. 
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We have set up our experiments in such a way that the effect of passage was also studied.  
When Wharton’s jelly cells reach a point where they could be used for transplantation into 
humans and/or large animals, large numbers of cells may be needed per recipient.  Current 
clinical trial for mesenchymal stromal cell transplantation studies suggest that about 1-5 x 109 
cells will be needed in total:  (USA : Osiris GVHD  2x106/kg x8 doses  (60kg : 9.6 x108 cells) 
Europe : Le Blanc GVHD 1.2 x106/kg x2 (60kg : 2 x108 cells). Going by these numbers for 
Wharton’s jelly cells, a recipient who weights 60 kilograms would need 120 million cells (more 
are needed to cover cells used for quality control, validation studies, loss to handling and 
freeze/thaw).  To be able to get the number of cells at these numbers, Wharton’s jelly cells need 
to be passaged to seven or eight passages.  We found no effect of passage on either post thaw 
viability or expression profile of cell surface markers before and after freezing. 
In our second study, we reported for the first time, the effect of serum free-medium and 
different oxygen concentration on in vitro growth rate, expression of cell surface markers and 
ploidy of Wharton’s jelly cells.  With the use of serum, there is the possibility for contamination 
with animal proteins.  If the cells are to be used therapeutically, they have be grown in defined 
conditions i.e. serum free conditions.  Moreover, the 21% oxygen concentration that the cells are 
grown in routinely in the lab, is not physiological.  Physiologic oxygen is 2-5%.    Our 
experimental results indicate that Wharton’s jelly cells grow faster in physiological oxygen 
levels in vitro (5% oxygen as opposed to room air: 21% oxygen).   The results also indicate that 
the growth effects found in our 2% serum containing growth medium could be effectively 
replaced by a serum-free medium (containing growth factors Fibroblast Growth Factor and non 
essential amino acids) that does not affect the growth rate of Wharton’s jelly cells and expression 
of cell surface markers; oxygen tension does not have an effect on the expression of cell surface 
markers.  The cells were euploid, not aneuploid or polyploid, when grown in different growth 
conditions, this is an important quality control for transplanted cells.  The sensitivity of our assay 
may have prevented us from detecting any changes.  Clearly, there were no gross changes in 
ploidy between the groups analyzed.  Of course, the number of cords sampled needs to be 
increased prior to statistical testing. 
It is believed that the isolation of cells from Wharon’s jelly results in a mixed population 
that may contain stemmy cells, stromal cells and various progenitors.  Some would contend that 
stem cells are therapeutically more effective than stromal cells and other progenitors.  If the stem 
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cell subpopulation could be identified at early passage, they could be selected for, expanded and 
cryopreserved.  One of the characteristics of the stem cell subpopulation is their ability to form 
colonies.  The cells that form colonies are called Colony Forming Unit-Fibroblasts (CFU-F).  It 
would be worthwhile to identify CFU-F in Wharton’s jelly cells and evaluate the effect of serum 
and low oxygen on CFU-F expansion.  While increases in CFU-F are correlated with the number 
of mesenchymal stem cells, the ultimate test and gold standard for a mesenchymal stem cell is its 
ability to engraft long-term and contribute to cells of mesenchymal lineages such as  bone, fat 
and cartilage. 
It would be interesting to expand on the current experimental results.  Our group plans to 
quantitate the revitalization after thawing.  We are considering using our new Guava personal 
flow cytometer for this purpose.  We would also like to isolate the cells in serum free conditions 
and grow them in low oxygen from passage one.    It is interesting to note that Friedman et al., 
reported that Wharton’s jelly cells do not survive when frozen in freezing mixture containing 
autologous plasma.  We would like to investigate further on using human serum for freezing 
mixtures.    
In conclusion, in human Wharton’s jelly cells, 90% FBS and 10% DMSO results in 
maximum numerical post thaw viability and the freezing does not significantly affect the 
expression of surface markers CD13, CD44, CD49e, CD90 and CD105.  Human Wharton’s jelly 
cells grow faster in 5% oxygen conditions and the growth rate does not change with the 
replacement of serum containing medium with serum free medium.  These results help take the 
cells a step closer to clinical trials. 
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